JP2005514381A5 - - Google Patents

Download PDF

Info

Publication number
JP2005514381A5
JP2005514381A5 JP2003548836A JP2003548836A JP2005514381A5 JP 2005514381 A5 JP2005514381 A5 JP 2005514381A5 JP 2003548836 A JP2003548836 A JP 2003548836A JP 2003548836 A JP2003548836 A JP 2003548836A JP 2005514381 A5 JP2005514381 A5 JP 2005514381A5
Authority
JP
Japan
Prior art keywords
mixture
ethyl ester
ethyl acetate
acid ethyl
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003548836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514381A (ja
JP4176020B2 (ja
Filing date
Publication date
Priority claimed from GBGB0128996.6A external-priority patent/GB0128996D0/en
Application filed filed Critical
Publication of JP2005514381A publication Critical patent/JP2005514381A/ja
Publication of JP2005514381A5 publication Critical patent/JP2005514381A5/ja
Application granted granted Critical
Publication of JP4176020B2 publication Critical patent/JP4176020B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003548836A 2001-12-04 2002-12-03 Mglur5アンタゴニスト活性を有するアセチレン誘導体 Expired - Lifetime JP4176020B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0128996.6A GB0128996D0 (en) 2001-12-04 2001-12-04 Organic compounds
PCT/EP2002/013670 WO2003047581A1 (en) 2001-12-04 2002-12-03 Acetylene derivatives having mglur 5 antagonistic activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008179005A Division JP5036648B2 (ja) 2001-12-04 2008-07-09 Mglur5アンタゴニスト活性を有するアセチレン誘導体

Publications (3)

Publication Number Publication Date
JP2005514381A JP2005514381A (ja) 2005-05-19
JP2005514381A5 true JP2005514381A5 (https=) 2006-01-05
JP4176020B2 JP4176020B2 (ja) 2008-11-05

Family

ID=9926969

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003548836A Expired - Lifetime JP4176020B2 (ja) 2001-12-04 2002-12-03 Mglur5アンタゴニスト活性を有するアセチレン誘導体
JP2008179005A Expired - Lifetime JP5036648B2 (ja) 2001-12-04 2008-07-09 Mglur5アンタゴニスト活性を有するアセチレン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008179005A Expired - Lifetime JP5036648B2 (ja) 2001-12-04 2008-07-09 Mglur5アンタゴニスト活性を有するアセチレン誘導体

Country Status (31)

Country Link
US (4) US7348353B2 (https=)
EP (1) EP1453512B8 (https=)
JP (2) JP4176020B2 (https=)
KR (2) KR100959204B1 (https=)
CN (2) CN100430059C (https=)
AR (2) AR037682A1 (https=)
AT (1) ATE327755T1 (https=)
AU (1) AU2002358585B2 (https=)
BR (1) BR0214666A (https=)
CA (1) CA2466560C (https=)
CO (1) CO5590929A2 (https=)
CY (1) CY1105460T1 (https=)
DE (1) DE60211944T2 (https=)
DK (1) DK1453512T3 (https=)
EC (1) ECSP045139A (https=)
EG (1) EG24936A (https=)
ES (1) ES2263842T3 (https=)
GB (1) GB0128996D0 (https=)
HU (1) HU229429B1 (https=)
IL (1) IL161990A0 (https=)
MX (1) MXPA04005456A (https=)
MY (1) MY137774A (https=)
NO (1) NO327005B1 (https=)
NZ (1) NZ533266A (https=)
PE (1) PE20030640A1 (https=)
PL (1) PL212996B1 (https=)
PT (1) PT1453512E (https=)
RU (1) RU2341515C2 (https=)
TW (1) TWI328578B (https=)
WO (1) WO2003047581A1 (https=)
ZA (1) ZA200403713B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
EP2272509A1 (en) * 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR101572280B1 (ko) * 2007-10-12 2015-11-26 노파르티스 아게 파킨슨병의 치료를 위한 대사성 글루타메이트 수용체 조절제
AU2012254934B2 (en) * 2007-10-12 2013-10-17 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2320892A2 (en) * 2008-06-30 2011-05-18 Novartis AG Combination products
RU2513856C2 (ru) * 2008-08-12 2014-04-20 Новартис Аг Способы получения метилового эфира 4-оксооктагидроиндол-1-карбоновой кислоты и ее производные
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
CN102573842A (zh) 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
US20130052644A1 (en) 2010-04-30 2013-02-28 Baltazar Gomez-Mancilla Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS)
JP2013529622A (ja) 2010-06-24 2013-07-22 ノバルティス アーゲー 1h−キナゾリン−2,4−ジオンの使用
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012084873A1 (en) 2010-12-20 2012-06-28 Novartis Ag 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
WO2012101058A1 (en) 2011-01-24 2012-08-02 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
KR20140003580A (ko) 2011-01-27 2014-01-09 노파르티스 아게 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도
WO2012127393A1 (en) 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
CN103889427A (zh) 2011-09-07 2014-06-25 诺华股份有限公司 1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
GB201215033D0 (en) 2012-08-23 2012-10-10 Novartis Ag Diazepinone derivatives
CN105263492B (zh) 2013-01-15 2018-04-10 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
BR112015016992A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
KR102290249B1 (ko) 2013-06-12 2021-08-17 노파르티스 아게 변형 방출 제제
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
CN105669686B (zh) * 2014-11-19 2018-08-03 上海合全药业股份有限公司 一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法
CA3067688A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
CA3124931A1 (en) 2019-01-29 2020-08-06 Novartis Ag The use of an mglur5 antagonist for treating opioid analgesic tolerance
BR112022005579A2 (pt) * 2019-11-05 2022-06-21 Claes Thulin 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para uso na prevenção e/ou no tratamento de surmenage em um mamífero
MX2023000664A (es) * 2020-07-17 2023-02-27 Novartis Ag Uso de antagonistas de mglur5.
IL303248A (en) 2020-12-11 2023-07-01 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
AU2021404023A1 (en) 2020-12-14 2023-06-29 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2741009A1 (de) * 1976-09-22 1978-03-23 Sandoz Ag 4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
DE2802833A1 (de) 1978-01-23 1979-07-26 Sandoz Ag 4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
US5264456A (en) 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
DE69634822T2 (de) 1995-08-22 2006-04-27 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE69915472T2 (de) 1998-06-04 2004-08-19 Kumiai Chemical Industry Co., Ltd. Phenylacetylenderivate und bakterizide für landwirtschaft und gartenbau
EP1117403B1 (en) 1998-10-02 2003-12-10 Novartis AG Mglur5 antagonists for the treatment of pain and anxiety
EP1200073B1 (en) 1999-07-06 2007-01-10 Eli Lilly And Company SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
GB0007108D0 (en) 2000-03-23 2000-05-17 Novartis Ag Organic compounds
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
MXPA03004862A (es) * 2000-12-04 2005-02-14 Hoffmann La Roche Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato.
GB0103045D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
US7138404B2 (en) 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
JP2005517640A (ja) 2001-12-04 2005-06-16 エフ.ホフマン−ラ ロシュ アーゲー 置換2−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2005514381A5 (https=)
KR880001426B1 (ko) 세팔로스포린 제조용 중간체의 제조방법
CA2481742C (fr) Procedes de preparation de combretastatines
JPH11263764A5 (https=)
JPH0583550B2 (https=)
CN112479967B (zh) 胆绿素类化合物及其制备方法和用途
JP2769058B2 (ja) シクロプロパン誘導体の製法
JPS621392B2 (https=)
BE858864A (fr) Nouveaux esters d'acides phenyl- et pyridine-3-carboxylique et procede permettant leur preparation
JP2716243B2 (ja) N―ベンジル―3―ヒドロキシスクシンアミド酸およびその製造法
CN110590641B (zh) 一种3-羟基异吲哚-1-酮系列化合物的绿色制备方法
JPH069553A (ja) 1−[|2s|−メチル−3−メルカプトプロピオニル−ピロリジン−|2s|−カルボン酸の製法
FR2541998A1 (fr) (3rs,4rs)-benzyl-4-cyanomethyl-3-(1'-hydroxyethyl)-2-azetidinone
JPH06184108A (ja) 5−クロロオキシインドールの製造方法
JPH0129793B2 (https=)
US5153330A (en) Thiapentanamide derivatives
JP2671401B2 (ja) α‐アミノチオアセトアミド誘導体およびその製造法
JP3224584B2 (ja) 2,3−ジヒドロインドール−3,3−ジカルボン酸及び2,3−ジヒドロインドール−3−カルボン酸誘導体
JPH01168664A (ja) シクロヘキセノン誘導体およびその製造法
JPS6125716B2 (https=)
JPS5935369B2 (ja) 光学活性化合物の立体選択的合成法
JP2006298872A (ja) 1−フルオロ−1−フェニルチオエテンの製造方法
JPH0459315B2 (https=)
CN102898373A (zh) Z-3-酰氧基-3-(1-乙基吡唑基)丙烯腈类化合物的制备方法
JPS58164573A (ja) 1−(4−クロロベンゾイル)−5−メトキシ−2−メチル−3−インド−ルアセトキシ酢酸類の製法